The drug Wegovy, already approved for weight loss in the United States, is now also authorized to reduce the risk of heart attack or stroke. This decision could make it possible to widely extend health insurance coverage for this drug, from the Danish group Novo Nordisk.
About 70% of American adults are obese or overweight, according to the FDA. It belongs to a new generation of treatments, imitating a gastrointestinal hormone (GLP-1), which have quickly become bestsellers around the world.